Richard D. Gelber

90.6k total citations · 19 hit papers
387 papers, 40.7k citations indexed

About

Richard D. Gelber is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard D. Gelber has authored 387 papers receiving a total of 40.7k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Oncology, 195 papers in Cancer Research and 92 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard D. Gelber's work include Breast Cancer Treatment Studies (189 papers), HER2/EGFR in Cancer Research (89 papers) and Estrogen and related hormone effects (69 papers). Richard D. Gelber is often cited by papers focused on Breast Cancer Treatment Studies (189 papers), HER2/EGFR in Cancer Research (89 papers) and Estrogen and related hormone effects (69 papers). Richard D. Gelber collaborates with scholars based in United States, Switzerland and Italy. Richard D. Gelber's co-authors include Aron Goldhirsch, Alan S. Coates, Beat Thürlimann, Hans-Jörg Senn, Stephen E. Sallan, W. C. Wood, Karen N. Price, Monica Castiglione‐Gertsch, John H. Glick and Steven E. Lipshultz and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Richard D. Gelber

379 papers receiving 39.4k citations

Hit Papers

Strategies for subtypes—d... 1980 2026 1995 2010 2011 1994 1995 1991 2009 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    2011 2.9k citations Aron Goldhirsch, Alan S. Coates et al. Annals of Oncology profile →
  2. Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
    1994 2.5k citations Edward M. Connor, Rhoda Sperling et al. New England Journal of Medicine profile →
  3. Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus 1 with Zidovudine Treatment
    1995 1.4k citations Edward M. Connor, Rhoda Sperling et al. profile →
  4. Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
    1991 1.0k citations Richard D. Gelber et al. New England Journal of Medicine profile →
  5. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
    2009 1.0k citations Aron Goldhirsch, Richard D. Gelber et al. Annals of Oncology profile →
  6. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    2017 918 citations Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine profile →
  7. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
    2005 886 citations Aron Goldhirsch, Richard D. Gelber et al. Annals of Oncology profile →
  8. The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology group
    1980 697 citations Richard D. Gelber et al. profile →
  9. Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
    2007 693 citations Alan S. Coates, Aparna Keshaviah et al. Journal of Clinical Oncology profile →
  10. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
    2017 688 citations David Cameron, Martine Piccart et al. The Lancet profile →
  11. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
    2007 680 citations Aron Goldhirsch, Richard D. Gelber et al. Annals of Oncology profile →
  12. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
    2018 666 citations Fabio Conforti, Laura Pala et al. profile →
  13. Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant
    1996 587 citations Rhoda Sperling, David E. Shapiro et al. New England Journal of Medicine profile →
  14. Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer
    1995 584 citations Richard D. Gelber et al. New England Journal of Medicine profile →
  15. Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
    1995 578 citations Richard D. Gelber et al. profile →
  16. Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
    2007 558 citations Richard D. Gelber et al. Journal of Clinical Oncology profile →
  17. Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
    2003 537 citations Aron Goldhirsch, Richard D. Gelber et al. Journal of Clinical Oncology profile →
  18. Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia
    2005 512 citations Richard D. Gelber et al. Journal of Clinical Oncology profile →
  19. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
    2016 378 citations Marco Colleoni, Zhuoxin Sun et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard D. Gelber United States 99 19.6k 14.3k 7.7k 5.4k 5.2k 387 40.7k
Seth M. Steinberg United States 124 29.1k 1.5× 7.9k 0.6× 13.6k 1.8× 8.1k 1.5× 3.9k 0.8× 864 58.9k
Gary H. Lyman United States 104 24.9k 1.3× 6.8k 0.5× 6.3k 0.8× 5.5k 1.0× 5.4k 1.0× 602 48.3k
Elisabeth G.E. de Vries Netherlands 102 24.1k 1.2× 6.4k 0.4× 7.4k 1.0× 3.4k 0.6× 2.4k 0.5× 1.0k 47.8k
Donna Neuberg United States 113 14.0k 0.7× 4.4k 0.3× 4.1k 0.5× 11.3k 2.1× 2.3k 0.4× 719 46.3k
Giovanni Scambia Italy 89 12.4k 0.6× 4.3k 0.3× 4.2k 0.5× 3.1k 0.6× 3.4k 0.7× 2.0k 49.2k
Hagop M. Kantarjian United States 171 28.5k 1.5× 7.0k 0.5× 7.3k 0.9× 18.9k 3.5× 3.8k 0.7× 3.4k 147.9k
Razelle Kurzrock United States 119 24.9k 1.3× 13.3k 0.9× 12.3k 1.6× 10.0k 1.9× 2.4k 0.5× 1.2k 60.4k
Patrick Maisonneuve Italy 108 17.1k 0.9× 10.4k 0.7× 7.2k 0.9× 6.7k 1.2× 3.0k 0.6× 567 41.9k
Ian F. Tannock Canada 95 16.6k 0.8× 8.1k 0.6× 16.7k 2.2× 1.3k 0.2× 2.2k 0.4× 426 44.1k
Julian Peto United Kingdom 63 8.2k 0.4× 3.3k 0.2× 5.8k 0.8× 3.5k 0.7× 3.7k 0.7× 158 34.8k

Countries citing papers authored by Richard D. Gelber

Since Specialization
Citations

This map shows the geographic impact of Richard D. Gelber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard D. Gelber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard D. Gelber more than expected).

Fields of papers citing papers by Richard D. Gelber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard D. Gelber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard D. Gelber. The network helps show where Richard D. Gelber may publish in the future.

Co-authorship network of co-authors of Richard D. Gelber

This figure shows the co-authorship network connecting the top 25 collaborators of Richard D. Gelber. A scholar is included among the top collaborators of Richard D. Gelber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard D. Gelber. Richard D. Gelber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maurer, Christian, Elisa Agostinetto, Lieveke Ameye, et al.. (2025). Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial. Breast Cancer Research and Treatment. 212(1). 57–69. 1 indexed citations
2.
Luen, Stephen J., Peter Savas, Roswitha Kammler, et al.. (2025). Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials. JCO Precision Oncology. 9(9). e2400599–e2400599. 1 indexed citations
3.
4.
Sun, Zhuoxin, Samuel M. Niman, Olivia Pagani, et al.. (2020). Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial. The Breast. 53. 1–7. 8 indexed citations
5.
Pondé, Noam, Dominique Agbor‐Tarh, Lissandra Dal Lago, et al.. (2020). Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). Breast Cancer Research and Treatment. 185(1). 107–116. 4 indexed citations
6.
7.
Filipits, Martin, Urania Dafni, Michael Gnant, et al.. (2018). Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clinical Cancer Research. 24(13). 3079–3086. 15 indexed citations
8.
Minckwitz, Gϋnter von, Marion Procter, Evandro de Azambuja, et al.. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine. 377(2). 122–131. 918 indexed citations breakdown →
9.
Rosenberg, Shoshana M., Shari Gelber, Richard D. Gelber, et al.. (2017). Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer. Journal of Adolescent and Young Adult Oncology. 6(3). 429–434. 25 indexed citations
10.
Cameron, David, Martine Piccart, Richard D. Gelber, et al.. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 389(10075). 1195–1205. 688 indexed citations breakdown →
11.
Metzger, Otto, Marion Procter, Evandro de Azambuja, et al.. (2013). Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. Journal of Clinical Oncology. 31(16). 1954–1960. 30 indexed citations
12.
Ewertz, Marianne, Kathryn P. Gray, Meredith M. Regan, et al.. (2012). Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. Journal of Clinical Oncology. 30(32). 3967–3975. 102 indexed citations
13.
14.
Maiorano, Eugenio, Meredith M. Regan, Giuseppe Viale, et al.. (2009). Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Research and Treatment. 121(1). 211–218. 34 indexed citations
15.
Rocca, Andrea, Giuseppe Viale, Richard D. Gelber, et al.. (2007). Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemotherapy and Pharmacology. 61(6). 965–971. 18 indexed citations
16.
Colleoni, Marco, Giuseppe Viale, David Zahrieh, et al.. (2007). Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Annals of Oncology. 19(3). 465–472. 82 indexed citations
17.
Mouridsen, Henning T., Aparna Keshaviah, Alan S. Coates, et al.. (2007). Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. Journal of Clinical Oncology. 25(36). 5715–5722. 93 indexed citations
18.
Rudenstam, Carl‐Magnus, David Zahrieh, John Forbes, et al.. (2005). Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. Journal of Clinical Oncology. 24(3). 337–344. 297 indexed citations
19.
Sperling, Rhoda, David E. Shapiro, Robert W. Coombs, et al.. (1996). Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. New England Journal of Medicine. 335(22). 1621–1629. 587 indexed citations breakdown →
20.
Anbazhagan, Rajakumar, Richard D. Gelber, R Bettelheim, Aron Goldhirsch, & B A Gusterson. (1991). Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Annals of Oncology. 2(1). 47–53. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seth M. Steinberg Breakdown of academic impact, for papers by Gary H. Lyman Breakdown of academic impact, for papers by Elisabeth G.E. de Vries Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by Giovanni Scambia Breakdown of academic impact, for papers by Hagop M. Kantarjian Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Patrick Maisonneuve Breakdown of academic impact, for papers by Ian F. Tannock Breakdown of academic impact, for papers by Julian Peto
Rankless by CCL
2026